Supriya Lifescience share price today

Supriya Lifescience Ltd's share price was ₹847.30 at the close on 30 October 2026. It has been rising for 22 weeks. That is 4.1% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹577 and ₹1,009, and at that close it sat 63% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Supriya Lifescience Ltd is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 1 week running.

Over the last 4.8 years the share price moved +75% while the NIFTY 500 moved +42%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 23 October 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Three changes stood out: profit fell in the June 2026 quarter, lowest operating margin in 11 quarters and revenue up on a year earlier for 4 quarters in a row.

1. Profit fell in the June 2026 quarter

   Profit was ₹24 crore, -31.4% on a year earlier (₹35 crore), after 3 quarters of growth.

   Why: Profit fell because power and solvent costs rose.

   Next results: check whether profit recovers as the operating margin moves back toward the yearly range.

   From the earnings call on 14 Aug 2026.

2. Lowest operating margin in 11 quarters

   Operating margin was 25% in the June 2026 quarter, against 36% a year earlier.

   Why: The operating margin fell because a water shortage at Lote for 15 to 20 days pushed back sales.

   Next results: check whether the operating margin recovers toward the yearly range.

   From the earnings call on 14 Aug 2026.

3. Revenue up on a year earlier for 4 quarters in a row

   In the June 2026 quarter revenue was ₹190 crore, +31% on a year earlier.

   Why: Revenue rose because demand stayed strong, even though a water shortage at Lote pushed some sales to a later date.

   Next results: check whether the sales pushed back from the June quarter show up, since management did not commit to a Q2 recovery.

   From the earnings call on 14 Aug 2026.

For April to June 2026 (the quarter ended 30 June 2026), Supriya Lifescience reported revenue of ₹190 crore, up 31.0% from ₹145 crore a year earlier, and a profit of ₹24.0 crore, down 31.4% from ₹35.0 crore.

Supriya Lifescience results: April to June 2026 against a year earlier

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

Supriya Lifescience's management discussed these results on a call held on 14 August 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.

Supriya Lifescience closed at ₹847.30 on 30 October 2026, up 9.1% from ₹776.90 a year earlier (31 October 2025) and up 238.1% over three years. Its highest weekly close since December 2021 was ₹1,009.30 on 1 July 2026.

Supriya Lifescience share price: then and now

Weekly closing prices. Each change is the move from that price to the 30 Oct 2026 close. A day's intraday high or low can go beyond these weekly closes.

260 weekly closes from 31 December 2021 to 30 October 2026.

30 Oct 2026: Supriya Lifescience closed at ₹847.30, up 3.5% on the week and down 9.0% on the month. 4 Sep 2026: ex-date for a dividend of ₹1 a share.

Earlier

• 14 Aug 2026: Supriya Lifescience held its results call for April to June 2026. Management guided: FY27 revenue milestone of ₹1,000 crore remains on track.
• Results for April to June 2026: Revenue up 31.0% and profit down 31.4% on a year earlier.

Supriya Lifescience paid ₹1 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 0.12% at the ₹847.30 close on 30 October 2026. The last was a dividend of ₹1 a share, ex-date 4 September 2026.

Supriya Lifescience dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date.

Yes. Supriya Lifescience Ltd paid out 4% of its profit as dividends in FY26, and it paid a dividend in 7 of its last 10 reported years.

From the NSE corporate-actions record, read 5 November 2026.

On the call for April to June 2026, held on 14 August 2026, Supriya Lifescience's management guided: FY27 revenue milestone of ₹1,000 crore remains on track.

“These challenges were largely external and transient in nature. Excluding these one-off impacts, margins would have remained within our guided range.”Shivani Wagh, Joint Managing Director, on the call for April to June 2026

What management guided

• FY27 operating margin 33-35%; one Q&A response used a different lower bound before later answers retained this range.
• Approximately 20% growth trajectory over the following 3-4 years; stronger H2FY27 ramp and non-linear quarterly delivery.
• Contrast media launch planned H2FY27; Ambernath EU audit scheduled for second half November and anesthetic API CEP expected October-November.
• Patalganga Phase 1 around ₹200 crore, API and utilities first; MIDC requires approximately 40% completion within 2.5 years; FY27 depreciation ₹35-40 crore, including ₹14-15 crore from Ambernath.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for April to June 2026, 14 August 2026.

What is changing at Supriya Lifescience, from the latest results and calls: cdmo and dsm partnership ramp, capacity expansion (patalganga & ambernath) and backward integration & pricing power.

• CDMO and DSM Partnership Ramp. DSM contract scaling to a higher peak, with new liquid anesthetic CMO contracts in advanced stages. ⚠ estimate
• Capacity Expansion (Patalganga & Ambernath). Phase-one capital spending at Patalganga and Ambernath semi-regulated commercialization unlocks new volume growth. ⚠ estimate
• Backward Integration & Pricing Power. Achieved high backward integration, protecting margins despite solvent price spikes. ⚠ estimate

We check 16 kinds of change in every company, such as costs spread over more sales, higher-value products, new orders, new regions or falling debt, against its reported numbers and what management said on its calls. Only changes the numbers back are shown.

Our read after the latest results, written 27 June 2026.

A delay in the Ambernath EU audit beyond the guided timeframe, or operating margin falling below historical ranges due to an inability to pass through solvent costs, would break the execution premium thesis.

Each change stops working if

• CDMO and DSM Partnership Ramp: The liquid anesthetic CMO term sheet falls through or is delayed beyond FY27.

The main risks

• Regulatory Audit Delays (Ambernath): Ambernath EU EMA audit expected soon; any delay stalls the margin-accretive regulated market ramp. ✓ fact
• Product Launch Delays (Contrast Media): Contrast media launch delayed for process optimization. ✓ fact

Our read after the latest results, written 27 June 2026.

When Supriya Lifescience reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: Q2 operating margin recovery toward the annual range - check cost normalization, production recovery and customer pass-through.

Supriya Lifescience is on one of our India lists: Pharma stocks.

Supriya Lifescience Ltd earned ₹24.0 Cr of net profit in the Jun 2026 quarter, −31.4% on the same quarter a year earlier. Full-year FY26 profit was ₹209 Cr. Over 9 years profit has grown 48.4% a year on average. That is 12.6% of the quarter's revenue. The same quarter a year earlier earned ₹35.0 Cr.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

For the full year, FY26 profit was ₹209 Cr (+11.2% on the year before).

Why profit moved: revenue changed +31.0% on a year earlier and the margin moved −11.0 percentage points. Sales did the work while the margin got thinner.

On average over the last four quarters, profit changed +7.9% and revenue +28.2%. Profit is growing slower than sales: rising costs are taking part of the growth.

Supriya Lifescience Ltd reported ₹190 Cr of revenue in the Jun 2026 quarter, +31.0% on the same quarter a year earlier. That is the 4th quarter in a row with growth on the year before. Over 9 years it has grown 18.2% a year on average. The last full year, FY26, came in at ₹828 Cr.

Revenue is everything the company billed its customers in the period.

Why this happened. The pivot to CDMO is materializing. With DSM volumes stabilized and liquid anesthetic CMO contracts in advanced term-sheet negotiations, this diversifies revenue away from pure API sales.

The last four reported quarters add to ₹873 Cr.

FY26 revenue was ₹828 Cr, +19.0% on the year before.

Recent pace: the last four quarters grew +28.2% on average, against 18.2% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +28.2%, against +20.7% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +11.2%, against +20.7% a year (rolling over).

Supriya Lifescience Ltd's operating margin was 25.0% in the Jun 2026 quarter, 11.0 percentage points lower than the same quarter a year ago. Across 10 years it has been between 9.0% and 44.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why this happened. Capacity constraints are being addressed. Patalganga groundbreaking and the F-block Lote extension provide the runway for the revenue goal and beyond.

Why the margin moved: operating margin changed −10.6 percentage points on the year while gross margin changed −7.8 points. So the drop came mostly from the gross margin, which means input costs and prices charged.

Over the last 3 years, 90% of Supriya Lifescience Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹186 Cr of operating cash against ₹209 Cr of profit. After ₹152 Cr of spending on assets, ₹34.0 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 90% of profit came in as cash: the cash cycle got 37 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives.

What to look at next: the bigger use of cash is spending on new assets, at 7.2× depreciation over three years. The next section checks what that spending is building.

Supriya Lifescience Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 167 days in FY26, up from 130 days in FY21. It spent ₹459 Cr on assets over the last 3 years. Customers take 97 days to pay, and stock sits for 229 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹828 Cr, each day of that cycle ties up about ₹2.3 Cr, so roughly ₹379 Cr is tied up in the business at any time.

FY26: customers took 97 days to pay and stock sat for 229 days, about 7.5 months of sales sitting as stock, for a full cycle of 167 days, longer than FY21's 130.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 229 days. Customers pay about 97 days after that. Suppliers are paid at 159 days. Together that makes the 167-day cycle.

Spending on assets: ₹459 Cr over the last 3 years, against ₹64.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹36.0 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Supriya Lifescience Ltd's P/E is 34.3×, near the high end of its own history: higher than 86% of past readings. Its usual P/E (the middle reading) is 27.9×, over 4.8 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

Why the multiple is where it is: over the past year earnings per share moved +11.3% while the price moved +9.1%. Earnings did better than the price, which pulled the multiple down within its own range.

Where the price move came from: over 3 years the price moved +50.1% a year; about +28.8% a year came from earnings growth and about +21.3 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple.

In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple.

Supriya Lifescience Ltd's business is growing steadily. Revenue, profit and EPS growth have stayed positive throughout, and ROCE is steady at 23.7%. This is based on 12 quarters of 4 measures.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: steady growth with healthy returns is how a business compounds over time.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Supriya Lifescience Ltd's story is not scored yet against the checks our research set on 27 June 2026. Where it sits in its own cycle: AT PEAK.

Still open: A delay in the Ambernath EU audit beyond the guided timeframe, or OPM falling below historical ranges due to an inability to pass through solvent costs, would break the execution premium thesis.

NOT YET CHECKED

From the price. Price stage 2, week 22, above its 200-day line, relative strength rising.

What is not proven yet. A delay in the Ambernath EU audit beyond the guided timeframe, or OPM falling below historical ranges due to an inability to pass through solvent costs, would break the execution premium thesis.

What would change our mind. A delay in the Ambernath EU audit beyond the guided timeframe, or OPM falling below historical ranges due to an inability to pass through solvent costs, would break the execution premium thesis.

The test written in advance. A delay in the Ambernath EU audit beyond the guided timeframe, or OPM falling below historical ranges due to an inability to pass through solvent costs, would break the execution premium thesis. Measured by: the thesis as written as stated by the next result.

The test written in advance. Regulatory Audit Delays (Ambernath). Measured by: Regulatory Audit Delays (Ambernath) EU audit scheduling confirmation in Q2/Q3 FY27 calls by the next result.

What the company does. FY26 revenue hit record highs with OPM steady, proving their ability to pass through raw material cost spikes. Regulatory hurdles cleared with a VAI for the Lote facility, and new capex is planned for Patalganga to support the revenue goal.

The key numbers to watch, and the level that would change the picture

Everything further down this page is evidence for or against these.

• 1 · Operating leveragebuilding
• 2 · Value-added mixbuilding
• 3 · Management changequiet
• 4 · Paying down debtquiet
• 5 · Regulatory approvalquiet
• 6 · Order-book winsbuilding
• 7 · Consolidationquiet
• 8 · Demerger or value unlockquiet
• 9 · Buybackquiet
• 10 · New geographiesquiet
• 11 · More business from existing customersquiet
• 12 · New product launchquiet
• 13 · Mandatory normsquiet
• 14 · A bigger market to servequiet
• 15 · Market-share gainsquiet
• 16 · Asset qualityquiet

Lever 6 · Order-book wins: building. DSM contract scaling to a higher peak, with new liquid anesthetic CMO contracts in advanced stages. What proves it keeps working: CDMO and DSM Partnership Ramp. It stops working if The liquid anesthetic CMO term sheet falls through or is delayed beyond FY27.

Lever 1 · Operating leverage: building. Phase-one capex at Patalganga and Ambernath semi-regulated commercialization unlocks new volume growth. What proves it keeps working: Capacity Expansion (Patalganga & Ambernath). It stops working if A delay in the Ambernath EU audit beyond the guided timeframe, or OPM falling below historical ranges due to an inability to pass through solvent costs, would break the execution premium thesis.

Lever 2 · Value-added mix: building. Achieved high backward integration, protecting margins despite solvent price spikes. What proves it keeps working: Backward Integration & Pricing Power. It stops working if A delay in the Ambernath EU audit beyond the guided timeframe, or OPM falling below historical ranges due to an inability to pass through solvent costs, would break the execution premium thesis.

Sources: our stock research file (27 June 2026) · quarterly results through Jun 2026 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes.

The whole page in one table. Each row links to its section.

What Supriya Lifescience Ltd's management promised, against what actually happened: 4 promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met.

ATS Volume Timing Reframed · 14 August 2026. In February 2026, management stated that it expected to fully achieve 250 to 300 tons in FY27. In August 2026, management said the 250-ton figure represented a two-year outcome and explicitly stated that it had not guided to that volume for FY27, materially changing the near-term volume assumption without reconciling the prior statement.

Contrast Media Timeline Deferred · 28 May 2026. In the November 2025 and February 2026 calls, management indicated the contrast media product would be launched in the fourth quarter of FY26. However, in the May 2026 call, they pushed this launch out to the second half of FY27 to perform further R&D on process optimization.

Cardiovascular Intermediate Volume Goal Contradicted · 28 May 2026. In the February 2026 call, management explicitly confirmed that the entire 250 to 300 metric tons of cardiovascular intermediate demand would be fully realized in FY27. However, in the May 2026 call, they changed this position, stating that these volumes will not come fully in FY27 and will instead manifest over the next two to three years.

Protein Project Revenue Forecast Cut · 28 May 2026. In the November 2025 call, management expected the Whey Protein contract to scale quickly and generate the majority of its potential revenue in FY27. However, in the May 2026 call, they stated that they do not see any large revenues coming from this project in FY27 as formulation development continues.

Every quote above is taken word for word from the company’s own earnings calls.

Supriya Lifescience Ltd earned a ROCE of 25% in FY26. That is up from a low of 14% in FY18. Its return on capital used (ROIC) is 5.0 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 25.2% net margin and 0.61× asset turnover (sales divided by assets).

Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.

Why the return is what it is (FY26): a 25.2% net margin × 0.61× asset turnover × 1.13× leverage (assets divided by equity) ≈ 17.4% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed.

The key test, return on capital used minus the cost of capital: 17.0% − 12.0% = +5.0 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Positive but thin: it creates value with little room for error.

The 17.0% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 19.8%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method.

Supriya Lifescience Ltd has total debt of ₹5.0 Cr against shareholder equity of ₹1,198 Cr as of Jun 2026, so its debt is 0.00× its equity, which is very little. Year by year, that ratio went from 0.04 in FY22 to 0.00 in FY26. So the returns on this page come from the business, not from borrowed money.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

No group of Supriya Lifescience Ltd's owners changed its stake by a full percentage point over the last two years. Promoters moved +0.0 points over the same period, to 68.3%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.

Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.

Over the last two years: Foreign institutions: +0.4 points over 8 quarters, to 6.5%; Promoters: +0.0 points over 8 quarters, to 68.3%; Domestic institutions: +0.0 points over 8 quarters, to 5.5%.

For Supriya Lifescience Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

43.7 out of 100, rank 17 of 24 in Pharma - API & CRAMS, with 96% of the evidence available.

Supriya Lifescience Ltd scores 43.7 out of 100 against the 24 companies it is compared with in Pharma - API & CRAMS, ranking 17. A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value.

The four parts add up to the total exactly: 15.6 + 16.9 + 6.2 + 5 = 43.7. This is the same number shown on the industry page; it is worked out once for the whole group and read here.

What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.

Supriya Lifescience ranks 17 of 24 Pharma - API & CRAMS companies on the 4-Factor Sector Score, with 43.7 out of 100.